- Home
- PACB vs ARVN Comparison
PACB vs ARVN Comparison
Compare PACB & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PACB | ARVN |
|---|---|---|
| Founded | 2000 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 715.5M | 806.0M |
| IPO Year | 2010 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PACB | ARVN |
|---|---|---|
| Price | $2.13 | $12.57 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 23 |
| Target Price | $2.00 | ★ $17.80 |
| AVG Volume (30 Days) | ★ 8.6M | 2.3M |
| Earning Date | 11-05-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $154,584,000.00 | ★ $312,300,000.00 |
| Revenue This Year | $4.41 | $11.06 |
| Revenue Next Year | $11.76 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 93.86 |
| 52 Week Low | $0.85 | $5.90 |
| 52 Week High | $2.73 | $22.48 |
Technical Indicators
Market Signals| Indicator | PACB | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 49.91 | 58.46 |
| Support Level | $2.30 | $12.47 |
| Resistance Level | $2.47 | $13.56 |
| Average True Range (ATR) | 0.20 | 0.54 |
| MACD | -0.03 | -0.03 |
| Stochastic Oscillator | 5.69 | 54.68 |
Price Performance
Historical ComparisonAbout PACB Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.